Jiangsu Hengrui Medicine
600276.SS
#494
Rank
NZ$71.50 B
Marketcap
$11.21
Share price
-0.62%
Change (1 day)
13.08%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Revenue for Jiangsu Hengrui Medicine (600276.SS)

Revenue in 2024 (TTM): NZ$5.88 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current revenue (TTM ) is NZ$6.43 Billion. In 2023 the company made a revenue of NZ$5.09 Billion an increase over the revenue in the year 2022 that were of NZ$4.95 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$5.88 B15.67%
2023 NZ$5.09 B2.69%
2022 NZ$4.95 B-15.39%
2021 NZ$5.85 B4.13%
2020 NZ$5.62 B12.91%
2019 NZ$4.98 B28.16%
2018 NZ$3.88 B33.65%
2017 NZ$2.90 B21.23%
2016 NZ$2.40 B11.28%
2015 NZ$2.15 B40.23%
2014 NZ$1.53 B24.76%
2013 NZ$1.23 B17.37%
2012 NZ$1.05 B15.57%
2011 NZ$0.90 B25.82%
2010 NZ$0.72 B18.19%
2009 NZ$0.61 B1.88%
2008 NZ$0.59 B75.96%
2007 NZ$0.34 B33.11%
2006 NZ$0.25 B21.23%
2005 NZ$0.21 B13.39%
2004 NZ$0.18 B-4.65%
2003 NZ$0.19 B11.92%
2002 NZ$0.17 B